肿瘤坏死因子拮抗剂治疗强直性脊柱炎的新进展
摘要
强直性脊柱炎(ankylosing spondylitis,AS)是一种以慢性炎症为主的全身性疾病,主要侵犯骶髂关节、脊柱骨突、脊柱旁软组织及外周关节。多见于青壮年,以18~22岁为发病高峰年龄,常导致青壮年疼痛、致残。由于其病因尚未完全明确,因此治疗上难有突破。相关研究表明,各种常用的改善病情的抗风湿药物(disease modifying antirheumatic drugs,DMARDs)难以迅速、有效地控制病情,而且对其他系统的副作用大。
出处
《美国医学会杂志(中文版)》
2008年第1期61-63,共3页
The Journal of the American Medical Association(Chinese Edition)
参考文献17
-
1Braun J, Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol. 1996 ;8:275-297.
-
2Gratacos J ,Collado A , Filella X , et al. Serum cytokines ( IL-6 ,TNF-α, IL-1βand IFN-γ) in ankylosing spondylitis : a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994 ;33:927-931.
-
3Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. New Engl J Med. 2002 ; 346 : 1349- 1356.
-
4Brandt J,Khariouzov A, Listing J,et al. Six-month results of a double-blind placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003 ;48 : 1667-1675.
-
5Inman RD, Clegg DO, Davis JC, et al. Etanercept in adult Patiens with early onset ankylosing spondylitis. J Rheumatol. 2006 ;33 : 1634-1636.
-
6Maksymowych WP, Poole AR, HiebertL, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol. 2005 ;32 : 1911-1917.
-
7Baraliakos X, Brandt J,Listing J. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data. Ann Rheum Dis. 2006 ;65:442-452.
-
8Brandt J, Haibel H, Comely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000;43:1346-1352.
-
9Brandt J, Haibel H,Sieper J, et al. hffliximab treatment of severe ankylosing spondylitis : one-year followup. Arthritis Rheum. 2001;44 : 2936-2937.
-
10Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002 ;359 : 1187-1193.
-
1阿达木单抗不会降低类风湿性关节炎患者对流感疫苗的应答[J].传染病网络动态,2007(9):3-3.
-
2伍伟,何东初.类风湿关节炎的生物治疗进展[J].华南国防医学杂志,2016,30(9):618-622. 被引量:4
-
3马喜喜,徐胜前.肿瘤坏死因子拮抗剂治疗类风湿关节炎的研究进展[J].临床内科杂志,2014,31(1):68-70. 被引量:2
-
4刘樱,许珂,张莉芸,高晋芳,马丹,侯建文,范秋玉.大剂量甲泼尼龙冲击治疗强直性脊柱炎髋关节病变疗效观察[J].中国药物与临床,2015,15(10):1464-1466. 被引量:5
-
5杜莹珏,田真,姚珍,张卓莉.肿瘤坏死因子拮抗剂治疗结缔组织病相关肺间质病变的现状[J].中华风湿病学杂志,2010,14(11):774-776. 被引量:1
-
6王雁,王晓蓉.类风湿关节炎患者抑郁情况调查分析[J].中国医药指南,2011,9(35):354-356. 被引量:1
-
7陈国阳,张清平,苏松森,陈永旺,苏密龙.肿瘤坏死因子拮抗剂对强直性脊柱炎患者血清相关细胞因子变化的影响及其机制研究[J].现代生物医学进展,2014,14(28):5486-5490. 被引量:6
-
8耿研,张卓莉.2015年美国风湿病学会/欧洲抗风湿联盟风湿性多肌痛管理推荐[J].中华临床免疫和变态反应杂志,2016,10(1):1-3. 被引量:11
-
9张挺,李永吉,朱小春.肿瘤坏死因子拮抗剂在类风湿关节炎中的应用进展[J].实用医学杂志,2012,28(4):523-525. 被引量:8
-
10张卓莉.生物制剂治疗类风湿关节炎经验与共识[J].中国实用内科杂志,2012,32(9):687-688. 被引量:7